How has been the historical performance of Roselabs Finance?

Answer:The historical performance of Roselabs Finance shows a gradual increase in net sales, reaching 0.71 Cr in March 2025, up from 1.14 Cr in March 2024 and starting from zero in the previous years. However, total operating income followed a similar trend, peaking at 1.14 Cr in March 2024 before declining to 0.71 Cr in March 2025. The company has consistently reported zero for other operating income and raw material costs, indicating limited operational activity. Total expenditure, excluding depreciation, was 1.02 Cr in March 2025, down from 1.31 Cr in March 2024. Operating profit (PBDIT) excluding other income was negative across the years, with a loss of 0.31 Cr in March 2025, reflecting a worsening trend from a loss of 0.17 Cr in March 2024. Profit before tax also remained negative, at -0.29 Cr in March 2025, compared to -0.13 Cr in March 2024. Profit after tax mirrored this trend, showing a loss of 0.29 Cr in March 2025, down from -0.13 Cr in March 2024. The earnings per share (EPS) were negative at -0.29 in March 2025, indicating ongoing financial struggles.

Breakdown:
Roselabs Finance's financial performance has been characterized by fluctuating revenues and persistent losses. The company recorded its first net sales in March 2023, with a significant drop in total operating income from 1.14 Cr in March 2024 to 0.71 Cr in March 2025. Despite this, total expenditure decreased slightly, but the operating profit margin remained deeply negative, reflecting operational inefficiencies. The company has not generated any interest income and has consistently reported losses in profit before and after tax, indicating ongoing financial distress. The book value per share has also deteriorated, reaching -4.73 in March 2025, while total liabilities have increased slightly, suggesting a growing debt burden. Overall, Roselabs Finance continues to face significant challenges in achieving profitability and managing its financial health.